X0306 4 2020-02-28 0 0001444380 NEVRO CORP NVRO 0001669489 Schmitz Patrick C/O NEVRO CORP. 1800 BRIDGE PARKWAY REDWOOD CITY CA 94065 0 1 0 0 Vice President, Operations Common Stock 2020-02-28 4 M 0 19583 57.89 A 38241 D Common Stock 2020-02-28 4 M 0 10833 87.62 A 49074 D Common Stock 2020-02-28 4 M 0 7312 76.81 A 56386 D Common Stock 2020-02-28 4 M 0 5156 42.30 A 61542 D Common Stock 2020-02-28 4 S 0 4604 126.4693 D 56938 D Common Stock 2020-02-28 4 S 0 7404 127.0628 D 49534 D Common Stock 2020-02-28 4 S 0 2758 128.2530 D 46776 D Common Stock 2020-02-28 4 S 0 17205 129.3381 D 29571 D Common Stock 2020-02-28 4 S 0 10313 130.1326 D 19258 D Common Stock 2020-02-28 4 S 0 600 130.825 D 18658 D Stock Option (Right to Buy) 57.89 2020-02-28 4 M 0 19583 0.00 D 2026-03-13 Common Stock 19583 417 D Stock Option (Right to Buy) 87.62 2020-02-28 4 M 0 10833 0.00 D 2026-11-15 Common Stock 10833 2500 D Stock Option (Right to Buy) 76.81 2020-02-28 4 M 0 7312 0.00 D 2027-11-13 Common Stock 7312 5688 D Stock Option (Right to Buy) 42.30 2020-02-28 4 M 0 5156 0.00 D 2028-11-26 Common Stock 5156 11344 D Includes 11,397 restricted stock units. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $125.69 to $126.685, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $126.695 to $127.69, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $127.70 to $128.695, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $128.71 to $129.705, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $129.72 to $130.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $130.74 to $130.95, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. 25% of the shares subject to the option vest on the first anniversary measured from March 14, 2016 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2016 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 14, 2017 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 27, 2018 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. /s/ Andrew Galligan, as Attorney-in-Fact for Patrick Schmitz 2020-03-03